Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies

Infliximab is a chimeric anti-tumour necrosis factor (TNF)-α antibody that is therapeutic in many patients with inflammatory bowel disease. What causes certain patients not to respond is unknown. The question posed is whether innate anti-TNF-α antibodies play any role in the response to infliximab....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ebert, E C, Das, K M, Mehta, V, Rezac, C
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2008
Assuntos:
Translational Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2633230/
https://ncbi.nlm.nih.gov/pubmed/18826498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.2008.03773.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados